ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Schizophrenia Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-0V3321
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Schizophrenia Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Schizophrenia Drugs Market Research Report 2025

Code: QYRE-Auto-0V3321
Report
September 2025
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson & Johnson
Bristol–Myers Squibb
Otsuka Pharma
Astrazeneca plc
Sumitomo Dainippon
Eli Lilly
Alkermes plc
Vanda Pharma
Allergan plc
Pfizer Inc

Schizophrenia Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Schizophrenia Drugs Market

Schizophrenia Drugs Market

The global market for Schizophrenia Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Schizophrenia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Schizophrenia Drugs.
The Schizophrenia Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Schizophrenia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Schizophrenia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Schizophrenia Drugs Market Report

Report Metric Details
Report Name Schizophrenia Drugs Market
CAGR 5%
Segment by Type
  • Oral Antipsychotics
  • Injectable Antipsychotics
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Johnson & Johnson, Bristol-Myers Squibb, Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan, Pfizer
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Schizophrenia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Schizophrenia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Schizophrenia Drugs Market report?

Ans: The main players in the Schizophrenia Drugs Market are Johnson & Johnson, Bristol-Myers Squibb, Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan, Pfizer

What are the Application segmentation covered in the Schizophrenia Drugs Market report?

Ans: The Applications covered in the Schizophrenia Drugs Market report are Hospital, Clinic

What are the Type segmentation covered in the Schizophrenia Drugs Market report?

Ans: The Types covered in the Schizophrenia Drugs Market report are Oral Antipsychotics, Injectable Antipsychotics

1 Schizophrenia Drugs Market Overview
1.1 Product Definition
1.2 Schizophrenia Drugs by Type
1.2.1 Global Schizophrenia Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Oral Antipsychotics
1.2.3 Injectable Antipsychotics
1.3 Schizophrenia Drugs by Application
1.3.1 Global Schizophrenia Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Schizophrenia Drugs Market Size Estimates and Forecasts
1.4.1 Global Schizophrenia Drugs Revenue 2020-2031
1.4.2 Global Schizophrenia Drugs Sales 2020-2031
1.4.3 Global Schizophrenia Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Schizophrenia Drugs Market Competition by Manufacturers
2.1 Global Schizophrenia Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Schizophrenia Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Schizophrenia Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Schizophrenia Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Schizophrenia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Schizophrenia Drugs, Product Type & Application
2.7 Global Key Manufacturers of Schizophrenia Drugs, Date of Enter into This Industry
2.8 Global Schizophrenia Drugs Market Competitive Situation and Trends
2.8.1 Global Schizophrenia Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Schizophrenia Drugs Players Market Share by Revenue
2.8.3 Global Schizophrenia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Schizophrenia Drugs Market Scenario by Region
3.1 Global Schizophrenia Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Schizophrenia Drugs Sales by Region: 2020-2031
3.2.1 Global Schizophrenia Drugs Sales by Region: 2020-2025
3.2.2 Global Schizophrenia Drugs Sales by Region: 2026-2031
3.3 Global Schizophrenia Drugs Revenue by Region: 2020-2031
3.3.1 Global Schizophrenia Drugs Revenue by Region: 2020-2025
3.3.2 Global Schizophrenia Drugs Revenue by Region: 2026-2031
3.4 North America Schizophrenia Drugs Market Facts & Figures by Country
3.4.1 North America Schizophrenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Schizophrenia Drugs Sales by Country (2020-2031)
3.4.3 North America Schizophrenia Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Schizophrenia Drugs Market Facts & Figures by Country
3.5.1 Europe Schizophrenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Schizophrenia Drugs Sales by Country (2020-2031)
3.5.3 Europe Schizophrenia Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Schizophrenia Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Schizophrenia Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Schizophrenia Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Schizophrenia Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Schizophrenia Drugs Market Facts & Figures by Country
3.7.1 Latin America Schizophrenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Schizophrenia Drugs Sales by Country (2020-2031)
3.7.3 Latin America Schizophrenia Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Schizophrenia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Schizophrenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Schizophrenia Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Schizophrenia Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Schizophrenia Drugs Sales by Type (2020-2031)
4.1.1 Global Schizophrenia Drugs Sales by Type (2020-2025)
4.1.2 Global Schizophrenia Drugs Sales by Type (2026-2031)
4.1.3 Global Schizophrenia Drugs Sales Market Share by Type (2020-2031)
4.2 Global Schizophrenia Drugs Revenue by Type (2020-2031)
4.2.1 Global Schizophrenia Drugs Revenue by Type (2020-2025)
4.2.2 Global Schizophrenia Drugs Revenue by Type (2026-2031)
4.2.3 Global Schizophrenia Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Schizophrenia Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Schizophrenia Drugs Sales by Application (2020-2031)
5.1.1 Global Schizophrenia Drugs Sales by Application (2020-2025)
5.1.2 Global Schizophrenia Drugs Sales by Application (2026-2031)
5.1.3 Global Schizophrenia Drugs Sales Market Share by Application (2020-2031)
5.2 Global Schizophrenia Drugs Revenue by Application (2020-2031)
5.2.1 Global Schizophrenia Drugs Revenue by Application (2020-2025)
5.2.2 Global Schizophrenia Drugs Revenue by Application (2026-2031)
5.2.3 Global Schizophrenia Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Schizophrenia Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Company Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Johnson & Johnson Schizophrenia Drugs Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Company Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bristol-Myers Squibb Schizophrenia Drugs Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Otsuka Pharma
6.3.1 Otsuka Pharma Company Information
6.3.2 Otsuka Pharma Description and Business Overview
6.3.3 Otsuka Pharma Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Otsuka Pharma Schizophrenia Drugs Product Portfolio
6.3.5 Otsuka Pharma Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Company Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AstraZeneca Schizophrenia Drugs Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Sumitomo Dainippon
6.5.1 Sumitomo Dainippon Company Information
6.5.2 Sumitomo Dainippon Description and Business Overview
6.5.3 Sumitomo Dainippon Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sumitomo Dainippon Schizophrenia Drugs Product Portfolio
6.5.5 Sumitomo Dainippon Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Company Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Eli Lilly Schizophrenia Drugs Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Alkermes
6.7.1 Alkermes Company Information
6.7.2 Alkermes Description and Business Overview
6.7.3 Alkermes Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Alkermes Schizophrenia Drugs Product Portfolio
6.7.5 Alkermes Recent Developments/Updates
6.8 Vanda Pharma
6.8.1 Vanda Pharma Company Information
6.8.2 Vanda Pharma Description and Business Overview
6.8.3 Vanda Pharma Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Vanda Pharma Schizophrenia Drugs Product Portfolio
6.8.5 Vanda Pharma Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Company Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Allergan Schizophrenia Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Company Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Schizophrenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Pfizer Schizophrenia Drugs Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Schizophrenia Drugs Industry Chain Analysis
7.2 Schizophrenia Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Schizophrenia Drugs Production Mode & Process Analysis
7.4 Schizophrenia Drugs Sales and Marketing
7.4.1 Schizophrenia Drugs Sales Channels
7.4.2 Schizophrenia Drugs Distributors
7.5 Schizophrenia Drugs Customer Analysis
8 Schizophrenia Drugs Market Dynamics
8.1 Schizophrenia Drugs Industry Trends
8.2 Schizophrenia Drugs Market Drivers
8.3 Schizophrenia Drugs Market Challenges
8.4 Schizophrenia Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Johnson & Johnson
Bristol–Myers Squibb
Otsuka Pharma
Astrazeneca plc
Sumitomo Dainippon
Eli Lilly
Alkermes plc
Vanda Pharma
Allergan plc
Pfizer Inc
List of Tables
 Table 1. Global Schizophrenia Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Schizophrenia Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Schizophrenia Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Schizophrenia Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Schizophrenia Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Schizophrenia Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Schizophrenia Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Schizophrenia Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Schizophrenia Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Schizophrenia Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Schizophrenia Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Schizophrenia Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Schizophrenia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Schizophrenia Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Schizophrenia Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Schizophrenia Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Schizophrenia Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Schizophrenia Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Schizophrenia Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Schizophrenia Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Schizophrenia Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Schizophrenia Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Schizophrenia Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Schizophrenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Schizophrenia Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Schizophrenia Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Schizophrenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Schizophrenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Schizophrenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Schizophrenia Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Schizophrenia Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Schizophrenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Schizophrenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Schizophrenia Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Schizophrenia Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Schizophrenia Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Schizophrenia Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Schizophrenia Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Schizophrenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Schizophrenia Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Schizophrenia Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Schizophrenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Schizophrenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Schizophrenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Schizophrenia Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Schizophrenia Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Schizophrenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Schizophrenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Schizophrenia Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Schizophrenia Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Schizophrenia Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Schizophrenia Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Schizophrenia Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Schizophrenia Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Schizophrenia Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Schizophrenia Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Schizophrenia Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Schizophrenia Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Schizophrenia Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Schizophrenia Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Schizophrenia Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Schizophrenia Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Schizophrenia Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Schizophrenia Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Schizophrenia Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Schizophrenia Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Schizophrenia Drugs Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Schizophrenia Drugs Price (USD/Unit) by Application (2026-2031)
 Table 70. Johnson & Johnson Company Information
 Table 71. Johnson & Johnson Description and Business Overview
 Table 72. Johnson & Johnson Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Johnson & Johnson Schizophrenia Drugs Product
 Table 74. Johnson & Johnson Recent Developments/Updates
 Table 75. Bristol-Myers Squibb Company Information
 Table 76. Bristol-Myers Squibb Description and Business Overview
 Table 77. Bristol-Myers Squibb Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Bristol-Myers Squibb Schizophrenia Drugs Product
 Table 79. Bristol-Myers Squibb Recent Developments/Updates
 Table 80. Otsuka Pharma Company Information
 Table 81. Otsuka Pharma Description and Business Overview
 Table 82. Otsuka Pharma Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Otsuka Pharma Schizophrenia Drugs Product
 Table 84. Otsuka Pharma Recent Developments/Updates
 Table 85. AstraZeneca Company Information
 Table 86. AstraZeneca Description and Business Overview
 Table 87. AstraZeneca Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. AstraZeneca Schizophrenia Drugs Product
 Table 89. AstraZeneca Recent Developments/Updates
 Table 90. Sumitomo Dainippon Company Information
 Table 91. Sumitomo Dainippon Description and Business Overview
 Table 92. Sumitomo Dainippon Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Sumitomo Dainippon Schizophrenia Drugs Product
 Table 94. Sumitomo Dainippon Recent Developments/Updates
 Table 95. Eli Lilly Company Information
 Table 96. Eli Lilly Description and Business Overview
 Table 97. Eli Lilly Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Eli Lilly Schizophrenia Drugs Product
 Table 99. Eli Lilly Recent Developments/Updates
 Table 100. Alkermes Company Information
 Table 101. Alkermes Description and Business Overview
 Table 102. Alkermes Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Alkermes Schizophrenia Drugs Product
 Table 104. Alkermes Recent Developments/Updates
 Table 105. Vanda Pharma Company Information
 Table 106. Vanda Pharma Description and Business Overview
 Table 107. Vanda Pharma Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Vanda Pharma Schizophrenia Drugs Product
 Table 109. Vanda Pharma Recent Developments/Updates
 Table 110. Allergan Company Information
 Table 111. Allergan Description and Business Overview
 Table 112. Allergan Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Allergan Schizophrenia Drugs Product
 Table 114. Allergan Recent Developments/Updates
 Table 115. Pfizer Company Information
 Table 116. Pfizer Description and Business Overview
 Table 117. Pfizer Schizophrenia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Pfizer Schizophrenia Drugs Product
 Table 119. Pfizer Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Schizophrenia Drugs Distributors List
 Table 123. Schizophrenia Drugs Customers List
 Table 124. Schizophrenia Drugs Market Trends
 Table 125. Schizophrenia Drugs Market Drivers
 Table 126. Schizophrenia Drugs Market Challenges
 Table 127. Schizophrenia Drugs Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Schizophrenia Drugs
 Figure 2. Global Schizophrenia Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Schizophrenia Drugs Market Share by Type: 2024 & 2031
 Figure 4. Oral Antipsychotics Product Picture
 Figure 5. Injectable Antipsychotics Product Picture
 Figure 6. Global Schizophrenia Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Schizophrenia Drugs Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Global Schizophrenia Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Schizophrenia Drugs Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Schizophrenia Drugs Sales (2020-2031) & (K Units)
 Figure 13. Global Schizophrenia Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 14. Schizophrenia Drugs Report Years Considered
 Figure 15. Schizophrenia Drugs Sales Share by Manufacturers in 2024
 Figure 16. Global Schizophrenia Drugs Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Schizophrenia Drugs Players: Market Share by Revenue in Schizophrenia Drugs in 2024
 Figure 18. Schizophrenia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Schizophrenia Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Schizophrenia Drugs Sales Market Share by Country (2020-2031)
 Figure 21. North America Schizophrenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 22. U.S. Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Schizophrenia Drugs Sales Market Share by Country (2020-2031)
 Figure 25. Europe Schizophrenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Schizophrenia Drugs Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Schizophrenia Drugs Revenue Market Share by Region (2020-2031)
 Figure 33. China Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Taiwan Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Philippines Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Schizophrenia Drugs Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Schizophrenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Schizophrenia Drugs Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Schizophrenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Schizophrenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Schizophrenia Drugs by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Schizophrenia Drugs by Type (2020-2031)
 Figure 55. Global Schizophrenia Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Schizophrenia Drugs by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Schizophrenia Drugs by Application (2020-2031)
 Figure 58. Global Schizophrenia Drugs Price (USD/Unit) by Application (2020-2031)
 Figure 59. Schizophrenia Drugs Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions